Katz, Sharyn I <br/><br/>
Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.  [electronic resource] 

 -  Cancer biology & therapy  Dec 2009 
 - 2406-16 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1555-8576 
<br/><br/><label>Standard No.: </label>10.4161/cbt.8.24.10824  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Apoptosis<br/>Benzenesulfonates--pharmacology<br/>Caspase 3--metabolism<br/>Cell Line, Tumor<br/>Extracellular Signal-Regulated MAP Kinases--antagonists & inhibitors<br/>Female<br/>Humans<br/>Lung Neoplasms--metabolism<br/>Mesothelioma--metabolism<br/>Mice<br/>Myeloid Cell Leukemia Sequence 1 Protein<br/>Neoplasm Transplantation<br/>Niacinamide--analogs & derivatives<br/>Phenylurea Compounds<br/>Phosphorylation<br/>Pleural Neoplasms--metabolism<br/>Proto-Oncogene Proteins c-bcl-2--metabolism<br/>Pyridines--pharmacology<br/>Sorafenib<br/>TNF-Related Apoptosis-Inducing Ligand--metabolism